课题基金 / 基金详情

Screening for anti-RSV compounds with indicator cells

Screening for anti-RSV compounds with indicator cells
用指示细胞筛选抗 RSV 化合物
批准号:
6582669
负责人:
Paul David Olivo
金额:
$41.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-07-01 至 2005-04-30

项目摘要

项目成果

Paul David Olivo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to use an infection-independent cell-based assay to identify compounds that inhibit respiratory syncytial virus (RSV). The basis of this bioassay is expression of a reporter gene from an artificial viral genome present within the cytoplasm of transfected cells. Significant advances have been made in identifying the cis-acting elements and trans-acting factors involved in replication of many pathogenic negative-strand RNA viruses including RSV. Negative-strand RNA viruses include some of the most notorious human pathogens and cause significant worldwide morbidity and mortality due to severe respiratory disease and hemorrhagic fever syndromes. Unfortunately very few therapeutic agents are available to treat infection with these viruses. Efforts to find new antiviral agents will require methods that are amenable to HTS. In this application the investigators describe their plans to use novel cell-based assays to identify compounds with anti-RSV activity. To identify 'hits' that inhibit replication of RSV the applicants plan to screen a unique library of natural compounds and several novel libraries of synthetic compounds. Apath's partner has developed a proprietary system for making compound libraries from plant-based material. High abundance compounds that lack drug like properties are removed, and the remaining compounds are chromatographically fractionated into distinct peaks, which are provided to Apath, LLC as arrays in bar-coded 96-well plates. Synthetic chemical libraries have been obtained from commercial sources that use novel approaches to make diverse compounds from well-conceived scaffolds. Antiviral activity of all 'hits' will be confirmed in secondary assays to measure inhibition of RSV directly. The investigators will identify compounds with the most promising chemical and biological profiles to pursue as potential anti-RSV drugs. The applicants also plan to identify the targets of the inhibitory compounds through biochemical and genetic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutics for Ebola virus
  • 批准号:
    6998649
  • 项目类别:
  • 资助金额:
    $135.0万
  • 财政年份:
    2005
  • 负责人:
    Paul David Olivo
  • 依托单位:
Molecular tools for Bunyavirus antiviral screening
  • 批准号:
    6736739
  • 项目类别:
  • 资助金额:
    $32.73万
  • 财政年份:
    2004
  • 负责人:
    Paul David Olivo
  • 依托单位:
Replicon-based screening for inhibitors of alphaviruses
  • 批准号:
    6911672
  • 项目类别:
  • 资助金额:
    $47.5万
  • 财政年份:
    2004
  • 负责人:
    Paul David Olivo
  • 依托单位:
Transgenic indicator cells for influenza virus
  • 批准号:
    7013204
  • 项目类别:
  • 资助金额:
    $27.29万
  • 财政年份:
    2004
  • 负责人:
    Paul David Olivo
  • 依托单位:
国内基金
海外基金
ITS-HPLC-HRMS-Bioassay多级筛选策略指导下海洋真菌中新型抗菌活性产物的发现